Gout & Hyperuricemia Drug Pipeline — PatSnap Eureka
Gout & Hyperuricemia Drug Pipeline: Uricase, XO Inhibitor & URAT1 Approaches
Three mechanistically distinct therapeutic modalities — pegylated uricase, xanthine oxidoreductase inhibition, and URAT1 blockade — define the current pharmacological landscape for gout and hyperuricemia. Explore the patent signals, key assignees, and combination strategies shaping this pipeline.
Understanding Gout and Hyperuricemia: The Molecular Targets
Hyperuricemia is defined as a biochemical state in which blood uric acid exceeds 7.0 mg/dL in men or 6.0 mg/dL in women, precipitating urate crystal deposition in joints, tendons, renal parenchyma, and soft tissues. Gout — manifesting as acute gouty arthritis, tophaceous gout, gouty nephropathy, and urolithiasis — is the principal clinical consequence, with serum uric acid (sUA) reduction as the pharmacological endpoint targeted across all three major modalities.
The most frequently targeted transporter is URAT1 (SLC22A12), the renal proximal tubule urate transporter responsible for the majority of urate reabsorption. Multiple assignees including life sciences innovators such as Japan Tobacco Inc., Teijin Pharma, J-Pharma, Sunshine Lake Pharma, Ardea Biosciences, and Arthrosi Therapeutics have filed patents targeting URAT1 inhibition. Co-cited transporters GLUT9 (SLC2A9) and NPT1/NPT4 are flagged as part of the broader urate excretion network.
Academic literature from the University of Otago and Radboud University Medical Center demonstrates that the ABCG2 Q141K variant (rs2231142) carries an odds ratio of 1.85 for progressing from hyperuricemia to symptomatic gout in Europeans and Polynesians — a pleiotropic genetic risk signal relevant to precision patient stratification. The NIH/NCBI literature base further supports ABCG2, GCKR, ALDH2, MAP3K11, and ALPK1 as genetic risk determinants flagged in patent filings from the University of Tokyo and Nariyoshi Shinomiya.
Xanthine oxidoreductase (XOR/XO) — the enzyme catalyzing the final two steps of purine degradation (hypoxanthine → xanthine → uric acid) — is inhibited by allopurinol and febuxostat-class compounds. Multiple patent landscape analyses identify Takeda Pharmaceuticals filings as the largest XOR inhibitor cluster in this dataset, explicitly referencing XOR inhibition for joint protection and renal preservation.
Three Mechanistic Approaches Defining the Pipeline
Patent filings and academic literature across the dataset reveal three primary pharmacological strategies, each with distinct mechanisms, assignee landscapes, and development stages.
Pegylated Uricase: Biologic Urate Degradation
Uricase enzymes catalyze oxidation of uric acid to allantoin, bypassing the metabolic block present in humans. PEGylated formulations extend half-life and reduce immunogenicity. Anti-drug antibody (ADA) formation — leading to treatment failure and infusion reactions — is the dominant engineering problem addressed across multiple Selecta Biosciences and Horizon Therapeutics patent families. Selecta's platform pairs pegsiticase with rapamycin-loaded synthetic nanocarriers (SVP-Rapamycin) to induce antigen-specific immune tolerance. Horizon's filings describe co-administration with methotrexate (MTX) and azathioprine, plus an optimized infusion protocol (<120 minutes, <250 mL volume).
Phase Ia clinical data referenced (Selecta IL filing)XO/XOR Inhibitors: Blocking Uric Acid Biosynthesis
XOR inhibition reduces de novo uric acid synthesis. Takeda Pharmaceuticals constitutes the largest single XOR inhibitor cluster in this dataset (CA, US, WO, AU, EP, HK, IN, BR, MX; 2007–2017), deploying XOR inhibitors across three distinct applications: prevention of gout flares when combined with NSAIDs, joint damage stabilization, and renal function preservation by reducing hyperuricemia-mediated tubulointerstitial injury. LG Chem's active 2023–2024 filings on an indole-pyrazole carboxylic acid compound specify 50–200 mg/day orally for 12 weeks, targeting sUA reduction to <6.0 mg/dL in ≥55% of patients with baseline sUA 8–12 mg/dL. Sunshine Lake Pharma filed dual XO + URAT1 inhibitor chemotypes.
LG Chem: active 2023–2024 clinical-stage filingsURAT1 Inhibitors: Enhancing Renal Urate Excretion
URAT1 inhibitors block the SLC22A12 transporter in the renal proximal tubule, enhancing urate excretion. This is the most chemically diverse modality in the dataset. Key assignees include J-Pharma (heterocyclic formula I derivatives), Teijin Pharma (pyridine derivatives for gout, hypertension, interstitial nephritis, diabetes), Ardea Biosciences (lesinurad-related series), Arthrosi Therapeutics (reduced CYP2C9 metabolic liability — explicit safety differentiation from benzbromarone), Cymabay Therapeutics (impaired renal function patients), and Shanton Pharma. Japan Tobacco Inc. references probenecid and benzbromarone as historical comparators.
Most structurally diverse modality in datasetAdjunct Agents & SGLT2 Inhibitors as Emerging Urate-Lowering Agents
Smaller modality clusters include diacerein/rhein (TWI Biotechnology; anthraquinone compounds for hyperuricemia and metabolic disorders), pentadienoic acid derivatives (Merck Santé), tetrazole compounds (Wellstat Therapeutics; uricosuric tetrazoles for gout, kidney stones, and cognitive impairment), and SNT2 inhibitors (Kissei Pharmaceutical). An observational database study (Sheu, 2020) analyzing approximately 300,000 adults with type 2 diabetes reported lower gout risk in SGLT2 inhibitor users vs. GLP-1 receptor agonist users — signaling an emerging urate-lowering role for dapagliflozin-class agents beyond diabetes management.
~300,000 adults in SGLT2 observational studyKey Assignees and Modality Distribution at a Glance
Patent filing signals from PatSnap Eureka, visualised across top assignees and therapeutic modalities in the gout and hyperuricemia drug pipeline.
Top Pipeline Assignees by Jurisdiction Coverage
Selecta Biosciences leads with 10+ jurisdictions for its pegylated uricase platform; Takeda's XOR inhibitor portfolio spans 9 jurisdictions (2007–2017).
Filing Activity Timeline by Modality (2006–2025)
XOR inhibitor filings peaked in the 2007–2013 Takeda era; URAT1 and uricase combination filings are the most active in 2017–2025.
Six Emerging Combination & Strategic Directions
Retrieved patent signals reveal a clear shift from single-agent paradigms toward multi-mechanism combinations, particularly for patients with concurrent CKD, heart failure, or metabolic syndrome.
Pegylated Uricase + Immunosuppressant
The most IP-active sub-field in the uricase category. Selecta Biosciences (nanocarrier-encapsulated rapamycin) and Horizon Therapeutics (systemic MTX or azathioprine) are pursuing independent but mechanistically complementary strategies to overcome ADA formation — the principal bottleneck for biologic urate-lowering therapy. Active filings as recent as 2024–2025.
URAT1 Inhibitor + XO Inhibitor (Dual Mechanism)
Sunshine Lake Pharma (WO 2017) and AstraZeneca (verinurad + XO inhibitor; WO 2018) both represent patented dual-mechanism strategies. Sunshine Lake's carboxyl-substituted heteroaromatic ring derivatives exhibit dual XO + URAT1 inhibitory activity — a mechanistically differentiated compound class relative to single-target agents.
AstraZeneca Triple Combination: URAT1 + XOR + SGLT2
AstraZeneca's filings (CA, SG, AU, WO, BR, MX; 2018–2021) describe a triple combination: verinurad (URAT1 inhibitor) + unnamed XO inhibitor + dapagliflozin (SGLT2 inhibitor), addressing hyperuricemia in the context of chronic kidney disease and heart failure — a cardiorenal metabolic syndrome positioning strategy.
XOR Inhibitor + NSAID for Flare Prophylaxis
Multiple Takeda filings (2007–2011) claim co-administration of XOR inhibitors with NSAIDs for six months to prevent gout flares during urate-lowering therapy initiation — managing the flare paradox during treatment initiation. This is a clinically established but IP-covered strategy.
Who Is Filing in the Gout & Hyperuricemia Space?
The innovation landscape in this dataset is predominantly patent-driven, with academic literature contributing genetic and epidemiological evidence. Selecta Biosciences has the largest single patent family in this dataset — pegylated uricase plus nanocarrier immunosuppressant platform filed across 10+ jurisdictions (US, WO, CA, AU, EP, IL, IN, MX; 2017–2024). Horizon Therapeutics holds multiple filings on pegloticase combination with immunosuppressants and optimized infusion protocols (US, CA, EP, WO, BR; 2019–2025).
Takeda Pharmaceuticals North America holds the largest XOR inhibitor portfolio in this dataset (CA, US, WO, AU, EP, HK, IN, BR, MX; 2007–2017) — now older filings suggesting mature or expiring IP. AstraZeneca AB has filed triple combination patents (verinurad + XO inhibitor + dapagliflozin) in CA, SG, AU, WO, BR, MX (2018–2021), signaling a cardiometabolic disease expansion strategy. The patent analytics picture is complemented by EPO-filed families from European-based assignees including Teijin Pharma and Shanton Pharma.
Academic assignees include the University of Tokyo / Nariyoshi Shinomiya (gout onset molecule identification and diagnostic kit patents; US, CA, EP, JP; 2015–2017), the National Health Research Institute (Taiwan; ALPK1 diagnostic patent, US 2009), and the University of Florida Research Foundation (urate-lowering agents for diabetes/insulin resistance prevention, JP 2009). Literature contributors include the University of Otago, Radboud University Medical Center, Nizam's Institute of Medical Sciences, and Wayne Sheu's SGLT2 inhibitor study. The full customer intelligence use case for this space spans pharma, biotech, and academic drug discovery teams globally.
Asian assignees — including LG Chem (South Korea), Sunshine Lake Pharma (China), J-Pharma (Japan), Japan Tobacco Inc., and TWI Biotechnology (Taiwan) — collectively represent a significant and growing share of the URAT1 and XOR inhibitor filing activity in this dataset, as tracked across the PatSnap platform.
Pipeline Evidence: From Patent Claims to Clinical Data
Retrieved results contain identifiable clinical or translational signals ranging from Phase Ia data references to granular dosing claims consistent with late-stage development.
Selecta Biosciences SEL-212: Phase Ia Clinical Data Referenced
The IL jurisdiction filing for pegylated uricase + SVP-Rapamycin (SEL-212) references "Phase Ia clinical trial" data — specifically mean serum uric acid levels across 5 cohorts following a single intravenous infusion — and ADA measurements in non-human primates. This constitutes the clearest clinical-stage evidence in the dataset.
Phase Ia · 5 cohorts · single IV infusionLG Chem Indole-Pyrazole XOR Inhibitor: Quantified Phase II/III-Type Protocol
The Peru filing specifies a patient population (sUA 8–12 mg/dL), dose range (50–200 mg/day), duration (12 weeks), and response benchmark (≥55% achieving sUA <6.0 mg/dL) — language characteristic of a Phase II/III clinical protocol. This is the most granular clinical dosing claim for a novel XOR inhibitor in this dataset.
50–200 mg/day · 12 weeks · ≥55% respondersFebuxostat vs. Terminalia bellerica in CKD: Randomised Clinical Study
A randomized, double-blind, positive-controlled clinical study from Nizam's Institute of Medical Sciences (2020) compared febuxostat 40 mg/day against an aqueous extract of Terminalia bellerica in CKD patients with hyperuricemia (n=59 randomized). Febuxostat served as the active comparator, confirming its use in renally impaired populations.
n=59 · CKD · febuxostat 40 mg/daySGLT2 Inhibitors Reduce Gout Risk: ~300,000-Adult Observational Analysis
An academic paper (Sheu, 2020) describes a retrospective propensity-score-matched database analysis in type 2 diabetics showing lower gout incidence with SGLT2 inhibitors vs. GLP-1 agonists across approximately 300,000 adults. This is observational evidence only, not from an interventional trial for gout, but signals an emerging urate-lowering role for dapagliflozin-class agents.
~300,000 adults · observational · T2D populationWhat the Pipeline Signals Mean for Drug Developers & IP Strategists
Run your own gout pipeline competitive analysis
PatSnap Eureka's AI searches across 150M+ patent documents and scientific literature in seconds.
Gout & Hyperuricemia Drug Pipeline — key questions answered
Three mechanistically distinct therapeutic approaches define the current and pipeline pharmacological landscape: uricase-based urate degradation, xanthine oxidase/oxidoreductase (XO/XOR) inhibition of uric acid biosynthesis, and URAT1-mediated blockade of renal urate reabsorption.
The central immunological challenge is anti-drug antibody (ADA) formation leading to treatment failure and infusion reactions. This is the dominant engineering problem addressed across multiple Selecta Biosciences and Horizon Therapeutics patent families.
The Peru filing for LG Chem's 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid specifies 50–200 mg/day orally for 12 weeks in patients with sUA 8–12 mg/dL, targeting reduction to less than 6.0 mg/dL in at least 55% of patients — a quantified clinical endpoint claim consistent with a late-stage development asset.
Academic literature from the University of Otago and Radboud University Medical Center demonstrates that the ABCG2 Q141K variant (rs2231142) is associated with both elevated serum urate and a disproportionately elevated risk of progressing from hyperuricemia to gout (OR = 1.85 in Europeans and Polynesians), suggesting a role beyond urate elevation alone.
AstraZeneca has filed on a triple combination of verinurad (URAT1 inhibitor) plus an XO inhibitor plus dapagliflozin (SGLT2 inhibitor) in CA, SG, AU, WO, BR, MX jurisdictions (2018–2021), signaling a cardiometabolic disease expansion strategy. Sunshine Lake Pharma has filed on dual XO/URAT1 inhibitor compounds. Selecta Biosciences and Horizon Therapeutics are each pursuing pegylated uricase combined with immunosuppressants.
An observational database study (Sheu, 2020) reporting lower gout risk in SGLT2 inhibitor users vs. GLP-1 receptor agonist users in type 2 diabetes patients (approximately 300,000 adults analyzed) signals an emerging urate-lowering role for dapagliflozin-class agents beyond diabetes management. SGLT2 inhibitors appear to secondarily reduce sUA reabsorption via their renal glycosuria mechanism.
Still have questions? Let PatSnap Eureka answer them for you.
Ask Eureka About the Gout PipelineAccelerate Your Gout & Hyperuricemia Drug Discovery
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D across uricase, XOR inhibitor, and URAT1 modalities.
References
- URAT1 inhibitor — J-Pharma Co., Ltd., 2021, ES [Patent]
- Carboxyl-substituted (hetero)aromatic ring derivatives and method of preparation and uses thereof — Sunshine Lake Pharma Co., Ltd., 2021, ES [Patent]
- Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof — Sunshine Lake Pharma Co., Ltd., 2017, WO [Patent]
- Methods for stabilizing joint damage in subjects using xanthine oxidoreductase inhibitors — Gunawardhana/Takeda, 2011, WO [Patent]
- Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors — Takeda Pharmaceuticals North America, Inc., 2010, WO [Patent]
- Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents — Taneja/Takeda, 2008, WO [Patent]
- A Pharmaceutical Composition Including 1-(3-Cyano-1-Isopropyl-Indol-5-Yl)Pyrazol-4-Carboxyl Acid — LG Chem, Ltd., 2024, PE [Patent]
- Pharmaceutical Composition Comprising 1-(3-Cyano-1-Isopropyl-Indole-5-Yl)Pyrazole-4-Carboxylic Acid — LG Chem, Ltd., 2024, BR [Patent]
- Formulations and doses of pegylated uricase — Selecta Biosciences, Inc., 2024, EP [Patent]
- Methods of treating gout — Horizon Therapeutics Ireland DAC, 2022, WO [Patent]
- Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect — Horizon Pharma Rheumatology LLC, 2020, WO [Patent]
- Novel compounds and compositions and methods of use — Ardea Biosciences Inc., 2012, AU [Patent]
- Pyridine derivative — Teijin Pharma Limited, 2018, ES [Patent]
- University of Otago & Radboud University Medical Center — ABCG2 Q141K genetic association studies, 2020 [Academic Literature]
- NIH/NCBI — Nizam's Institute of Medical Sciences: Febuxostat vs. Terminalia bellerica in CKD (n=59), 2020 [Clinical Paper]
- European Patent Office (EPO) — Gout and hyperuricemia patent families [Reference Database]
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.